Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
about
Alemtuzumab for patients with chronic lymphocytic leukaemiaThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cUpdate on chronic lymphocytic leukemia: overview of new agents and comparative analysis.The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Management of chronic lymphocytic leukemia.Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions.Choosing first-line therapy for chronic lymphocytic leukemia.miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.Therapeutic antibodies against cancer.Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.What is the best frontline therapy for patients with CLL and 17p deletion?Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Emerging antibody combinations in oncology.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?What do we do with chronic lymphocytic leukemia with 17p deletion?Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.Use of non-irradiated blood components in Campath (alemtuzumab)-treated renal transplant patients.Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran.Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.Infectious complications in chronic lymphocytic leukemia.Outcomes in critically ill chronic lymphocytic leukemia patients.How I treat patients with relapsed chronic lymphocytic leukaemia.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia
P2860
Q24203628-08B83F73-3982-44B5-B4E7-F08EBE2DA325Q24617708-FAADDE15-FC44-4871-B3AC-C5416301D1CBQ28082086-18762445-F87C-46D8-BF3B-A23D2EC0202EQ30408922-BFF4AB95-88DD-4AE6-BCCD-50C490727486Q33406478-7AA722C3-12C7-4D2B-B55F-694EE66AA4A6Q33558740-E835D15D-8F42-40AD-BDCA-BFDAFE3545D9Q33695912-751048A2-8BE8-4D39-AFA6-0072CB5264F1Q34008593-3BB831D2-A12C-4D93-B59D-BEFB6CF4BD02Q34456583-23234226-EA02-431A-B621-99CA82D8299AQ35124844-9DA24B7F-AB45-4159-B5F7-75B44A0C1392Q35582556-E36975CC-1443-40E8-AC22-35FFF33B766EQ35680158-EE767C5F-579C-4495-A195-3F66B4829F78Q35908498-22EF1631-AC31-4307-844E-F0244EBF2B60Q37065666-139E3515-F39E-4AFA-9622-8DA4F54F95BEQ37154344-C6231D41-FDC4-45BB-9D92-169883539A4FQ37820433-A01ABB65-DA08-4103-968B-9480B1878944Q37842484-083417A7-5145-410B-AA17-5A279D1F50CEQ37854714-F480EB53-D939-4099-9991-EFA3B464192BQ37893414-540DFEF0-F678-4696-8981-42CB09761D77Q37919869-60849A54-390A-48C6-BB0F-4EA80D5EF03FQ37975154-E67456FA-EBE3-4EE8-8F32-392F1B82808CQ38063170-830D0F18-996B-4A5E-9B04-6B95AF14CEE8Q38110472-2F0A5E09-1394-4517-B0F3-5704F277C3C6Q38263490-49C11AC9-D00D-4845-8F1C-C71EEE0C7AE5Q38650602-901D04A0-5C7F-4365-9352-37667E526012Q38782334-8EECA9E6-1F7C-4D94-A472-1B7B85DFE44FQ38866636-68D47C32-5D39-4696-BF18-DF4C09D5BF80Q39264020-8BE01C8A-7430-4E3C-8742-67887A3D44F5Q39544646-A1D57F0C-955A-4017-94B5-AD67949E8834Q39994604-98F4FEF5-E7D7-4910-B5D5-8C496C5BEA02Q40403542-768244B9-ECAF-45D2-A6BC-1254209968D3Q42277456-E896139B-C0C8-4EEC-AC38-C58C8994E565Q44413722-0438AB8F-1847-41B5-90AA-DB64F1556291Q54348577-11464DF1-B9B0-4F6C-BE9D-5AEFF8803225Q54534916-9429ACCA-BBEB-48B8-B79F-DC6E583A2BF0Q59126180-267BE788-CC20-4764-89D0-C34EC611EF01
P2860
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Consolidation therapy with sub ...... final analysis of CALGB 10101
@ast
Consolidation therapy with sub ...... final analysis of CALGB 10101
@en
Consolidation therapy with sub ...... final analysis of CALGB 10101
@nl
type
label
Consolidation therapy with sub ...... final analysis of CALGB 10101
@ast
Consolidation therapy with sub ...... final analysis of CALGB 10101
@en
Consolidation therapy with sub ...... final analysis of CALGB 10101
@nl
prefLabel
Consolidation therapy with sub ...... final analysis of CALGB 10101
@ast
Consolidation therapy with sub ...... final analysis of CALGB 10101
@en
Consolidation therapy with sub ...... final analysis of CALGB 10101
@nl
P2093
P2860
P356
P1476
Consolidation therapy with sub ...... final analysis of CALGB 10101
@en
P2093
Elizabeth M Bengtson
Eva E Hoke
James N Atkins
John C Byrd
Kanti R Rai
Kathleen A Donohue
Margaret S Lucas
Thomas S Lin
P2860
P304
P356
10.1200/JCO.2010.29.7978
P407
P577
2010-08-09T00:00:00Z